Lycia Therapeutics, Inc., a leader in extracellular protein degradation has appointed Steve Staben, Ph.D., as Chief Scientific Officer. Prior to joining Lycia, Dr. Staben spent over 14 years at Genentech leading drug discovery programs in oncology and immunology as well as new modality platforms.

Steve has co-authored over 70 peer-reviewed articles and patent applications and holds his Ph.D. in organic chemistry from the University of California, Berkeley.